Inmazeb ® (a three-antibody cocktail consisting of maftivimab, atoltivimab and odesivimab-ebgn) was the first Ebola treatment approved by the ...

Regeneron Pharmaceuticals will partner with Parabilis Medicines to discover and develop an initial five candidates ...

Drugs in development to treat and prevent infections caused by the Ebola virus that’s circulating in the Democratic Republic of Congo and Uganda should be given only as part of clinical trials, ...

LONDON - Initial results from a large study in the U.K. found that an antibody drug reduced death in hospitalized COVID-19 patients who faced the highest risk from the virus. The study was led by the ...

The phase 3 trial was evaluating two doses of anti-LAG-3 antibody fianlimab in combination with PD-1 inhibitor Libtayo ...

The multi-target collaboration combines Regeneron’s industry-leading antibody capabilities with Parabilis’ novel Helicon™ peptide platform ...